Compare HAWK & KARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HAWK | KARD |
|---|---|---|
| Founded | 2015 | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.9B |
| IPO Year | 2026 | 2026 |
| Metric | HAWK | KARD |
|---|---|---|
| Price | $14.63 | $14.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | $32.56 | ★ $42.25 |
| AVG Volume (30 Days) | ★ 1.2M | 500.6K |
| Earning Date | 11-12-2026 | 08-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $84.87 | N/A |
| Revenue Next Year | $24.92 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $15.21 | $13.75 |
| 52 Week High | $25.71 | $27.00 |
| Indicator | HAWK | KARD |
|---|---|---|
| Relative Strength Index (RSI) | 28.61 | 32.59 |
| Support Level | N/A | $13.75 |
| Resistance Level | $17.42 | $22.81 |
| Average True Range (ATR) | 0.68 | 1.22 |
| MACD | 0.02 | -0.15 |
| Stochastic Oscillator | 2.26 | 21.59 |
Hawkeye 360 Inc operates in the signals intelligence (SIGINT) and defense technology sector. It provides end-to-end signals intelligence solutions integrated into national security systems for the United States and allied customers. Its offerings include radio frequency data and related insights to support defense operations. The company is involved across the value chain, including satellite design and manufacturing, data collection, and data processing and analysis. It generates revenue prominently from fixed price contract arrangements for RF signal mapping products that are used to analyze and track radio waves.
Kardigan Inc is a clinical-stage therapeutics company focused on developing medicines for cardiovascular diseases. Its activities include the research and development of targeted therapies for cardiovascular conditions for which no approved treatments currently exist. The company's clinical-stage programs include Danicamtiv, Ataciguat, and Tonlamarsen, which are being developed for cardiovascular disease indications. The company operates and manages its business as a single operating and reportable segment, focused on the discovery and development of novel therapeutic products to treat cardiovascular disease.